Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment.
about
Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide.TNF-α-induced LRG1 promotes angiogenesis and mesenchymal stem cell migration in the subchondral bone during osteoarthritis.Population Pharmacokinetics of Lenalidomide in Healthy Volunteers and Patients With Hematologic Malignancies.Clinical pharmacokinetics of oral drugs in the treatment of multiple myeloma.Lenalidomide improvement of cisplatin antitumor efficacy on triple-negative breast cancer cells in vitro.
P2860
Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Pharmacokinetics, safety, and ...... myeloma and renal impairment.
@en
Pharmacokinetics, safety, and ...... myeloma and renal impairment.
@nl
type
label
Pharmacokinetics, safety, and ...... myeloma and renal impairment.
@en
Pharmacokinetics, safety, and ...... myeloma and renal impairment.
@nl
prefLabel
Pharmacokinetics, safety, and ...... myeloma and renal impairment.
@en
Pharmacokinetics, safety, and ...... myeloma and renal impairment.
@nl
P2093
P2860
P1476
Pharmacokinetics, safety, and ...... myeloma and renal impairment.
@en
P2093
Bertrand Arnulf
Eric Moumas
Estelle Desport
Frank Bridoux
Jean Paul Fermand
Julie Abraham
Nianhang Chen
Stephane Moreau
P2860
P2888
P304
P356
10.1007/S00280-016-3068-9
P577
2016-06-10T00:00:00Z